Gilead Sciences reports fiscal Q3 2025 results: revenue $7.77B, up 3% from a year earlier

Gilead Sciences filed a Form 8-K with the SEC on Oct 30, 2025, 4:04 PM ET, reporting an event dated Oct 30, 2025. It covers Item 2.02 (Results of Operations and Financial Condition); Item 9.01 (Financial Statements and Exhibits). The results cover fiscal Q3 2025 (quarter ended Sep 30, 2025); figures below are from the company's XBRL financial data filed with the SEC.

• Revenue: $7.77B (+3.0% from $7.54B a year earlier)
• Operating income: $3.33B (+274.7% from $888.0M a year earlier)
• Net income: $3.05B (+143.6% from $1.25B a year earlier)
• Diluted EPS: $2.43 (+143.0% from $1.00 a year earlier)
• Form 8-K accepted by EDGAR Oct 30, 2025, 4:04 PM ET
• Accession number 0000882095-25-000044

SEC filing 8-K · accession 0000882095-25-000044 · sec.gov ↗